Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...
PALO ALTO, Calif. & SECAUCUS, N.J., September 24, 2025--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, and Quest ...
Guardant Health and Quest Diagnostics Announce Strategic Collaboration to Broaden Access to Guardant’s Shield™ Blood-based Screening Test in the United States Collaboration to enable streamlined and ...
Collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network Shield is the first and only blood test to receive full ...